Vaxart starts Ph1 oral vax trial

San Francisco-based Vaxart has started dosing patients in its first Phase I trial using its oral vaccine platform. The study uses an H5N1 flu vaccine, but the platform, if effective, could be used with several other vaccines. The trial will take place in the U.S. Vaxart release

Launch Readiness

Optimize cross-functional collaboration and engage with key stakeholders for the successful launch of a product

Join the Launch Readiness for Medical Affairs & Communications Teams Summit to learn best practices in taking a structured approach to enhance medical affairs activities surrounding a launch and increase knowledge and communication with thought leaders.